Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1987 3
1988 1
1989 2
1991 11
1992 5
1993 4
1995 2
1996 6
1997 7
1998 5
1999 1
2000 2
2001 1
2002 3
2003 4
2004 2
2005 2
2006 4
2007 3
2008 5
2009 5
2010 2
2011 7
2012 6
2013 4
2014 1
2015 3
2016 3
2017 3
2018 4
2019 5
2020 5
2021 8
2022 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

132 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ajana f[au]
Your search for Adan AF[au] retrieved no results
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
Osiyemi O, De Wit S, Ajana F, Bisshop F, Portilla J, Routy JP, Wyen C, Ait-Khaled M, Leone P, Pappa KA, Wang R, Wright J, George N, Wynne B, Aboud M, van Wyk J, Smith KY. Osiyemi O, et al. Among authors: ajana f. Clin Infect Dis. 2022 Sep 29;75(6):975-986. doi: 10.1093/cid/ciac036. Clin Infect Dis. 2022. PMID: 35079789 Free PMC article. Clinical Trial.
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
van Wyk J, Ajana F, Bisshop F, De Wit S, Osiyemi O, Portilla Sogorb J, Routy JP, Wyen C, Ait-Khaled M, Nascimento MC, Pappa KA, Wang R, Wright J, Tenorio AR, Wynne B, Aboud M, Gartland MJ, Smith KY. van Wyk J, et al. Among authors: ajana f. Clin Infect Dis. 2020 Nov 5;71(8):1920-1929. doi: 10.1093/cid/ciz1243. Clin Infect Dis. 2020. PMID: 31905383 Free PMC article. Clinical Trial.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Jaeger H, Overton ET, Richmond G, Rizzardini G, Andrade-Villanueva JF, Mngqibisa R, Hermida AO, Thalme A, Belonosova E, Ajana F, Benn PD, Wang Y, Hudson KJ, Español CM, Ford SL, Crauwels H, Margolis DA, Talarico CL, Smith KY, van Eygen V, Van Solingen-Ristea R, Vanveggel S, Spreen WR. Jaeger H, et al. Among authors: ajana f. Lancet HIV. 2021 Nov;8(11):e679-e689. doi: 10.1016/S2352-3018(21)00185-5. Epub 2021 Oct 11. Lancet HIV. 2021. PMID: 34648734 Clinical Trial.
Endoscopic treatment of a liver hydatid cyst with biliary rupture.
Borahma M, Jebari Y, Chabib FZ, Lagdali N, Benelbarhdadi I, Ajana FZ. Borahma M, et al. Among authors: ajana fz. Endoscopy. 2022 Aug;54(8):E456-E457. doi: 10.1055/a-1625-4316. Epub 2021 Sep 27. Endoscopy. 2022. PMID: 34571556 No abstract available.
Chagas disease, France.
Lescure FX, Canestri A, Melliez H, Jauréguiberry S, Develoux M, Dorent R, Guiard-Schmid JB, Bonnard P, Ajana F, Rolla V, Carlier Y, Gay F, Elghouzzi MH, Danis M, Pialoux G. Lescure FX, et al. Among authors: ajana f. Emerg Infect Dis. 2008 Apr;14(4):644-6. doi: 10.3201/eid1404.070489. Emerg Infect Dis. 2008. PMID: 18394284 Free PMC article.
[Hepatitis B virus still under debate].
Ajana F. Ajana F. Arch Pediatr. 2006 Sep;13(9):1269-74. doi: 10.1016/j.arcped.2006.06.014. Epub 2006 Aug 22. Arch Pediatr. 2006. PMID: 16920340 Review. French.
Macrophage activation syndrome during Crohn´s disease: a case report.
Kharmach O, Lagdali N, Benelbarhdadi I, Borahma M, Ajana FZ. Kharmach O, et al. Among authors: ajana fz. Pan Afr Med J. 2022 Jun 6;42:97. doi: 10.11604/pamj.2022.42.97.29361. eCollection 2022. Pan Afr Med J. 2022. PMID: 36034004 Free PMC article.
Assessment of intra-sample variability in HIV-1 DNA drug resistance genotyping.
Millière L, Bocket L, Tinez C, Robineau O, Veyer N, Wojciechowski F, Lambert V, Meybeck A, Huleux T, Ajana F, Hober D, Alidjinou EK. Millière L, et al. Among authors: ajana f. J Antimicrob Chemother. 2021 Jul 15;76(8):2143-2147. doi: 10.1093/jac/dkab149. J Antimicrob Chemother. 2021. PMID: 34050668
Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials.
Orkin C, Ajana F, Kityo C, Koenig E, Natukunda E, Gandhi-Patel B, Wang H, Liu Y, Wei X, White K, Makadzange T, Pikora C, McNicholl I, Collins SE, Brainard D, Chuck SK. Orkin C, et al. Among authors: ajana f. J Acquir Immune Defic Syndr. 2021 Dec 1;88(4):393-398. doi: 10.1097/QAI.0000000000002789. J Acquir Immune Defic Syndr. 2021. PMID: 34506342 Free PMC article. Clinical Trial.
132 results